Key result
Gut microbiome dysbiosis is linked to allograft rejection, infection, and vasculopathy after heart transplantation.
The gut microbiome is emerging as a modifiable factor in heart transplant outcomes, offering potential for novel predictive biomarkers and targeted therapies to improve long-term allograft survival.
Heart transplantation remains the gold standard therapy for patients with end-stage heart failure. However, post-transplant complications are considerable. Emerging evidence implicates the gut microbiome as a modifiable determinant of post-heart transplant outcomes through its influence on host immunity, metabolism, and inflammation. This Review synthesizes current understanding of gut microbiome dysregulation following solid organ transplantation, with particular emphasis on heart transplantation, examining mechanistic links underpinning important complications including allograft rejection, infection, metabolic dysfunction, and cardiac allograft vasculopathy. We critically evaluate bidirectional interactions between the gut microbiome and immunosuppressive drugs, assess the potential for microbiome profiling to serve as a predictive biomarker for post-transplant complications, and examine microbiome-targeted interventions including dietary modification, prebiotics, probiotics, and fecal microbiota transplant. Finally, we propose a translational roadmap to integrate microbiome science into heart transplant care to optimize immunosuppression, predict complications, and improve long-term outcomes for heart transplant recipients.
No takes yet. Share an insight, caveat, or question.
Ðuran et al. (2026) conducted a review in Heart transplantation. Gut microbiome was evaluated. The gut microbiome acts as a modifiable determinant of post-heart transplant outcomes, with dysregulation linked to allograft rejection, infection, and cardiac allograft vasculopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: